LncRNA TUG1, a tumor oncogene associated with various human cancers, has been reported to be involved in regulating various cellular processes, such as proliferation, apoptosis and invasion through targeting multiple genes. However, its biological function in thyroid cancer cells has not been elucidated. The aim of this study is to measure TUG1 expression level and evaluate its function in thyroid cancer cells. LncRNA TUG1 expression levels in thyroid cancer tissues and three thyroid cancer cell lines (the ATC cell lines SW1736 and KAT18 and the FTC cell line FTC133) were assessed by qRT-PCR and compared with that of the human normal breast epithelial cell HGC-27. MTT assay, colony formation assay, transwell assay and western blot analysis were performed to assess the effects of TUG1 on proliferation, metastasis and EMT formation in thyroid cancer cells in vitro. Rescue assay was performed to further confirm that TUG1 contributes to the progression of thyroid cancer cells through regulating miR-145/ZEB1 signal pathway. LncRNA TUG1 was found to be up-regulated in thyroid cancer tissues and thyroid cancer cells compared with that in the human normal breast epithelial cell HGC-27. Increased lncRNA TUG1 expression was found to significantly promote tumor cell proliferation, and facilitate cell invasion, while down-regulated TUG1 could obviously inhibit cell proliferation, migration/invasion and reverse EMT to MET. These results indicated that TUG1 may contribute to the progression of thyroid cancer cells by function as a ceRNA competitive sponging miR-145, and that lncRNA TUG1 is associated with tumor progression in thyroid cancer cells.
Introduction
Thyroid cancer is a common type of malignancy in endocrine organs with steadily increasing incidence rates over the past 10 years [1] . Despite the development of treatments for patients with thyroid cancer, the 5-year cancer-specific survival rate still remains unsatisfied. The initiation and progression of thyroid cancer are complex processes. Therefore, further understanding and revealing the pathogenetic mechanism underlying thyroid cancer are indispensable for the development of effective diagnosis and treatments.
Long non-coding RNAs (lncRNAs), generally defined as transcripts longer than 200 nucleotides, have captured significant attention in carcinogenesis. Many lncRNAs, such as MALAT1, H19, and HOTAIR, have been demonstrated as critical regulators of carcinogenesis and development of many cancers [2] [3] [4] [5] [6] . Recently, a novelpost-transcriptional regulation has been proposed in which lncRNAs interact with miRNAs, functioning as competing endogenous RNAs (ceRNAs) [7, 8] . Taurine up-regulated gene 1 (TUG1), an lncRNA located at chromosome 22q12, was originally identified to contribute to the formation of photoreceptors and play crucial roles in retinal development [9] . Recently, TUG1 has been reported to be dys-regulated in many cancers [10] [11] [12] [13] [14] . However, the function of TUG1 in thyroid cancer cells still remains unclear.
In the current study, we comprehensively investigated the biologic functions of TUG1 in thyroid cancer cells. Our results showed that TUG1 was up-regulated in thyroid cancer tissues and cells. Moreover, further experiments indicated that overexpression of TUG1 could promote proliferation, migration/invasion and EMT formation of the thyroid cancer cell lines, and this function was mainly dependent on the regulating signal pathway miR-145/ ZEB1.
Materials and Methods

Tissues and cell lines
Thyroid cancer tissues and pair-matched noncancerous tissues were obtained from 36 patients diagnosed with thyroid cancer at The Second Hospital of Dalian Medical University. Informed consent was obtained from all patients.
Three human thyroid cell lines (the ATC cell lines SW1736 and KAT18 and the FTC cell line FTC133) and human normal breast epithelial HGC-27 cells were obtained from the Tumor Cell Bank of the Chinese Academy of Medical Science (Shanghai, China). Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Gibco, Carlsbad, USA) supplemented with 10% bovine calf serum. Cells were maintained at 37°C in an atmosphere of humidified air with 5% CO 2 .
Cell transfection
pcDNA3.1/TUG1 (pcDNA3.1 as control), shTUG1 (shRNA as control), miR-145 mimics and inhibitor were purchased from Applied Biological Materials (ABM, Vancouver, Canada). Transfections were performed using the Lipofectamine 2000 kit (Invitrogen, Carlsbad, USA) according to the manufacturer's instructions.
Real-time quantitative reverse-transcription polymerase chain reaction (qRT-PCR)
Total RNA from tissues and cells was isolated with Trizol reagent (Invitrogen) according to the manufacturer's instructions. Reverse transcription was performed with PrimeScript RT Reagent Kit (Takara, Dalian, China) according to the manufacturer's protocol. qRT-PCR was performed with SYBR Prime Script RT-PCR Kit (Takara) based on the manufacturer's instructions. The levels of miR-145, TUG1 and ZEB1 were calculated using the 2 −ΔΔCt method, and normalized to the level of U6 or GAPDH mRNA, respectively. All assays were performed in triplicate. The expression levels were expressed as the fold change relative to the corresponding controls which were defined as 1.0. The primers used are listed in Table 1 . 
Cell viability
Colony formation assay
Cells were plated at 500 cells/well in 6-well plates and incubated in DMEM with 10% bovine calf serum at 37°C. Two weeks later, the cells were fixed and stained with 0.1% crystal violet. The number of visible colonies was counted manually.
Cell migration and invasion assays
Cell migration and invasion was measured using transwell chamber (8-μm pore size; Corning Co., Corning, USA) without/with Matrigel (Becton Dickinson, New York, USA). At 48 h after transfection, cells in serum-free media were placed into the upper chamber without or with 10 μg/ml Matrigel. Medium containing 10% bovine calf serum was added into the lower chamber. After 48 h of incubation, cells remaining in the upper membrane were wiped off, while cells that migrated across the membrane were fixed with methanol, stained with 0.1% crystal violet and counted under a microscope. Three independent experiments were carried out.
Dual luciferase reporter assay
pmirGLO-TUG1-WT or pmirGLO-TUG1-MUT was co-transfected with miR-145 mimics or miR-NC into HEK293 cells by Lipofectamine 2000-mediated gene transfer. The relative luciferase activity was normalized to Renilla luciferase activity 48 h after transfection. The data were expressed as the fold change relative to the corresponding control groups which were defined as 1.0.
RNA immunoprecipitation (RIP)
RIP was performed using Thermo Fisher RIP kit (Thermo Fisher, New York, USA) based on the manufacturer's protocol. The Ago2 antibodies are purchased from Abcam (Cambridge, USA). Normal mouse IgG (Abcam) was used as the negative control (NC) and anti-SNRNP70 (Abcam) was employed as the positive control for the RIP procedure. Purified RNA was subject to qRT-PCR analysis to demonstrate the presence of the binding targets using the primers listed in Table 1 . 
RNA-pull down assay
LncRNA-TUG1 transcripts were transcribed by using T7 RNA polymerase (Roche, Basel, Switzerland) in vitro, then the RNeasy Plus Mini Kit (Qiagen, Valencia, USA), and treated with DNase I (Qiagen). Purified RNAs were biotin-labeled with the Biotin RNA Labeling Mix (Roche). Then, magnetic beads were added to each binding reaction mixture and incubated at room temperature for 1 h. Finally, the beads were washed, and the eluted proteins were detected by western blot analysis.
Western blot analysis
Total protein was extracted from cells and tumor tissues using RIPA lysis buffer. Extracted proteins were mixed with loading buffer, subject to 10% SDS-PAGE and transferred to PVDF membranes. Membranes were blocked with 5% (v/v) milk and incubated with the corresponding primary antibodies in 5% (w/v) bovine serum albumin (BSA) at 4°C overnight, followed by incubation with the corresponding horseradish peroxidase-conjugated secondary antibodies. Membranes were washed three times for 15 min, and the signals were detected using an enhanced chemiluminescence-detecting kit (Thermo Fisher), followed by analysis with Tanon 5200 Chemiluminescent Imaging System (BioTanon, Shanghai, China). Primary antibodies used are antibodies against E-cadherin (1:2000 dilution), N-cadherin (1:2000 dilution), and GAPDH (1:3000), which were all purchased from Abcam.
Statistical analysis
Data are shown as the mean ± standard error of at least three independent experiments. The SPSS 17.0 software (SPSS Inc., Chicago, USA) was used for statistical analysis. Two group comparisons were performed with a Student's t-test. Multiple group comparisons were analyzed with one-way ANOVA. The correlation between the TUG1 and ZEB1 expression levels, between the TUG1 and miR-145 expression levels, and between the TUG1 and ZEB1 expression levels in 36 cases of thyroid tissues were analyzed by Spearman's correlation analysis. All tests performed were two-sided. P < 0.05 was considered statistically significant.
Results
TUG1 is up-regulated in thyroid cancer tissues and thyroid cancer cells
To explore the function and mechanism of TUG1 in thyroid cancer, we first detected the TUG1 expression in 36 pairs of thyroid cancer tissues and corresponding histologically normal tissues. TUG1 levels were increased in cancerous tissues (P < 0.01) (Fig. 1A) when compared with those in matched noncancerous tissues. Additionally, we also measured the level of TUG1 in three human thyroid cell lines (the ATC cell lines SW1736 and KAT18 and the FTC cell line FTC133), with human normal breast epithelial cell line HGC-27 as the control. As shown in Fig. 1B , the TUG1 level was obviously increased in FTC133 and KAT18 cells compared with that in HGC-27 cells, and the TUG1 level in SW1736 cells was nearly as low as that in HGC-27 cells. These results indicated that TUG1 might be involved in the progression of the thyroid cancer.
High level of TUG1 regulates thyroid cancer cell proliferation and migration/invasion and EMT phenotype formation
Next, we examined the biological functions of TUG1 in thyroid cancer cells. TUG1 was overexpressed or down-regulated in SW1736 or FTC133 cells through transfection with TUG1 expression vector pcDNA3.1/TUG1 or TUG1-specific shRNA, with the empty vector or shRNA as the NC. The transfection efficiency was measured at 48 h post-transfection ( Fig. 2A) . Results from MTT assay and colony formation assay showed that enhanced proliferation ability was observed in TUG1-transfected SW1736 cells compared with NC-transfected cells; on the contrary, decreased proliferation ability of FTC133 cells transfected with shTUG1 was obtained compared with that of shRNAtransfected cells (P < 0.01; Fig. 2B,C) . Additionally, transwell assay showed that forced expression of TUG1 in SW1736 cells could significantly promote cell migration/invasion capability, and deletion of TUG1 could weaken the migration/invasion capacity of FTC133 cells (Fig. 2D) . Furthermore, results from western blot analysis showed that TUG1 contributed to the EMT formation of thyroid cancer cells (Fig. 2E) . These data together demonstrated that TUG1 was involved in the progression of thyroid cancer cells.
Identification of miR-145 as a target of TUG1
It has been reported that many lncRNAs are identified as ceRNAs for specific miRNAs. To examine whether TUG1 exerts its function in thyroid cancer as a ceRNA, we utilized the starbase software (http:// starbase.sysu.edu.cn/mirLncRNA.php) and measured the miRNAs predicted to bind with TUG1 to knockdown TUG1. FTC133 cells were transfected with shTUG1, and it was found that TUG1 knockdown had the most significant effect on miR-145 expression The level of TUG1 in three human thyroid cell lines (SW1736, KAT18 and FTC133). Human normal breast epithelial HGC-27 cells were used as the control. Data are presented as the mean ± SD of at least three independent experiments. *P < 0.05, **P < 0.01 vs. control group. Table S1 ). Additionally, TUG1 has been reported to physically associate with miR-145 [16] . Therefore, miR-145 was studied in detail. To explore the relationship between TUG1 and miR-145, we first examined the expression level of miR-145 in three thyroid cancer cells and human normal breast epithelial cells. As illustrated in Fig. 3A , the expression level of miR-145 was obviously decreased in FTC133 cells, and the level of miR-145 in SW1736 cells was nearly as high as that in HGC-27 cells. To further validate the regulatory relationship between TUG1 and miR-145, we performed an RIP assay and used the biotin-avidin pull down system. Results from RIP assay showed that TUG1 was detected in Ago2 immunoprecipitates from the control group, but the level of TUG1 was drastically reduced in Ago2 complexes purified from cells treated with miR-145 inhibitor, indicating that TUG1 is likely in the miR-145 RISC complex (Fig. 3B) . Results from RNA pull down showed that TUG1 was pulled down by miR-145, while miR-145-MUT with mutated bind site of TUG1 failed to pull down TUG1 (Fig. 3C) , indicating that TUG1 regulated miR-145 in a sequence-specific manner. Additionally, the results of luciferase reporter assay provided further confirmation. As shown in Fig. 3D , miR-145 mimics reduced the luciferase activity of wild-type TUG1 reporter vector (WT) but not that of mutant reporter vector (MUT). Furthermore, the expression level of miR-145 in response to dys-regulated TUG1 expression was examined. As shown in Fig. 3E , the expression level of miR-145 was negatively correlated Transwell and western blot analysis were applied to detect the function of TUG1 in cell migration and EMT phenotype formation. Data are presented as the mean ± SD of at least three independent experiments. *P < 0.05, **P < 0.01 vs. control group.
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with that of TUG1. These data confirmed the direct binding between TUG1 and miR-145.
miR-145 negatively regulates proliferation and invasion of thyroid cancer cells
To investigate the biological function of miR-145 in thyroid cancer cells, miR-NC or miR-145 mimics was transfected into FTC133 cells, and anti-miR-NC or miR-145 inhibitor was transfected into SW1736 cells. The transfection efficiency was satisfactory (Fig. 4A) . MTT and colony formation assays revealed weakened proliferation of FTC133 cells transfected with miR-145 mimics, and the opposite effect was obtained in SW1736 cells transfected with miR-145 inhibitor (P < 0.01; Fig. 4B,C) .
Moreover, transwell assay revealed that weakened metastasis capacity was observed in FTC133 cells transfected with miR-145 mimics, and an opposite phenomenon was observed in SW1736 cells transfected with miR-145 inhibitor (P < 0.01; Fig. 4D) . Additionally, as shown in Fig. 4E , overexpression of miR-145 could reverse the EMT phenotype of thyroid cancer cells. These data together suggested that miR-145 might be involved in the function exerted by TUG1 in thyroid cancer.
Oncogenic function of TUG1 in thyroid cancer cells is dependent on miR-145
Rescue experiments were carried out to determine whether TUG1 influences thyroid cancer cell proliferation and invasion in a miR-145-dependent manner. Anti-miR-NC or miR-145 inhibitor was transfected into FTC133 cells which had been stably transfected with shTUG1 or shRNA control, while miR-NC or miR-145 mimics were transfected into SW1736 cells which had been stably transfected with pcDNA3.1/TUG1 or control vector. MTT and colony formation assays showed that the weakened proliferation induced by shTUG1 in FTC133 cells was abrogated in part by the introduction of miR-145 inhibitor, and vice versa in SW1736 cells co-transfected with miR-145 mimics and pcDNA3.1/TUG1 (P < 0.01; Fig. 5A,B) . Likewise, transwell assay revealed that the weakened invasion capacity caused by shTUG1 was partially abolished by miR-145 inhibitor, and an opposite phenomenon was observed in SW1736 cells co-transfected with miR-145 mimics and pcDNA3.1/TUG1 (P < 0.01; Fig. 5C ). These data indicated that TUG1 contributed to the progression of thyroid cancer cells through targeting miR-145. 
TUG1 positively regulates the miR-145 target gene ZEB1 in thyroid cancer tissues
It has been reported that ZEB1 is a target of miR-145, and ZEB1 was reported to be involved in many cancers [17] . Therefore, we proposed that TUG1 and ZEB1 interact with miR-145 by functioning as a ceRNA. To confirm such model, we measured the level of ZEB1 in response to different levels of TUG1. It was found that in SW1736 cells, forced expression of TUG1 increased the level of ZEB1 (Fig. 6A) . In FTC133 cells, deletion of TUG1 suppressed the level of ZEB1 (Fig. 6A) . In addition, we employed rescue assay to confirm whether ZEB1 is involved in the function of TUG1. As shown in Fig. 6B -D, MTT, colony formation and transwell assays Figure 5 . The oncogenic function of TUG1 in thyroid cancer cells is dependent on miR-145 (A,B) MTT and colony formation assays were utilized to detect the proliferation ability of thyroid cancer cells co-transfected with shTUG1 (or TUG1) and miR-145 inhibitor (or miR-145 mimics). (C) Transwell assay was utilized to detect the migration capability of thyroid cancer cells co-transfected with shTUG1 (or TUG1) and miR-145 inhibitor (or miR-145 mimics). Data are presented as the mean ± SD of at least three independent experiments. *P < 0.05, **P < 0.01 vs. control group.
revealed that the weakened proliferation and migration ability induced by shTUG1 in FTC133 cells could be in part abrogated by the introduction of ZEB1. Furthermore, the expressions of ZEB1 and miR-145 in 36 paired samples of primary thyroid cancer tissues and corresponding non-carcinoma tissues were determined by qRT-PCR. The relative level of miR-145 in thyroid cancer tissues was significantly lower than those in the corresponding normal tissues, and the level of ZEB1 in thyroid cancer tissues was obviously higher than those in the corresponding normal tissues (P < 0.01; Fig. 6E ). Additionally, Figure 6 . TUG1 positively regulates the miR-145 target gene ZEB1 in thyroid cancer tissues (A) The level of ZEB1 in respond to the level of TUG1. (B-D) MTT, colony formation and transwell assays were performed to measure the proliferation and migration ability of thyroid cancer cells co-transfected with shTUG1 and ZEB1. (E) The relative levels of ZEB1 and miR-145 in thyroid cancer tissues were significantly higher than those in the corresponding normal tissues. (F) The correlation between miR-145 level and TUG1 level (2-tailed Spearman's correlation, r = −0.68, P < 0.01); and the correlation between ZEB1 level and TUG1 level (2-tailed Spearman's correlation, r = 0.859, P < 0.01). Data are presented as the mean ± SD of at least three independent experiments. *P < 0.05, **P < 0.01 vs. control group. miR-145 level and TUG1 level were negatively correlated (2-tailed Spearman's correlation, r = −0.68, P < 0.01; Fig. 6F ). What's more, the level of ZEB1 showed a positive correlation with TUG1 level (2-tailed Spearman's correlation, r = 0.859, P < 0.01; Fig. 6F ). Collectively, these data indicated that there is a regulatory signaling pathway in which TUG1 regulates ZEB1 by competitively sponging miR-145, inducing increased proliferation ability and enhanced migration capacity in thyroid cancer cells.
Discussion
The long non-coding RNAs (lncRNAs) are RNA molecules over 200 nucleotides in length with little protein-coding potential [17] . Accumulating evidence has shown that ncRNAs play a pivotal role in tumorigenesis in a wide repertoire of biological processes [18] [19] [20] . In 2016, Xue et al. [16] reported that lncRNA urothelial cancerassociated 1 promotes bladder cancer cell migration and invasion by way of the miR-145/ZEB1/2/FSCN1 pathway. Chen et al. [21] revealed that up-regulation of long non-coding RNA HOTTIP could promote metastasis of esophageal squamous cell carcinoma via induction of EMT. What's more, in 2016, lncRNA HOXA11-AS was reported to promote proliferation and invasion of gastric cancer by scaffolding the chromatin modification factors PRC2, LSD1, and DNMT1 [22] . Although many lncRNAs have been reported to regulate cancer progression, the roles of lncRNAs in the carcinogenesis of thyroid cancer are far from fully elucidated. Investigating the molecular mechanism by which lncRNAs function in thyroid cancer is critical for the discovery of novel therapeutic targets.
LncRNA TUG1 was initially identified as a transcript up-regulated by taurine, and siRNA-based depletion of TUG1 suppresses mouse retinal development [23] . The abnormal expression of TUG1 has been reported in many cancers [11] [12] [13] [14] [24] [25] [26] . It has been revealed that TUG1 could function as competing endogenous RNA, thereby releasing the miRNA-combined target genes or working via binding to polycomb repressive complex 2 (PRC2) [14] . Despite the implications of TUG1 in the regulation of a variety of transcription factors and physiological processes, the role of TUG1 in thyroid cancer remains unexplored. Our results confirmed the oncogenic role of TUG1 in thyroid, and identified that miR-145/ZEB1 signal pathway mediates the function of TUG1 in thyroid cancer cells.
In conclusion, our study was the first to investigate the role of TUG1 in thyroid cancer. The results indicated that TUG1 is a novel potential oncogene in thyroid cancer, and it is up-regulated in thyroid cancer tissues. TUG1 can promote the proliferation, migration and EMT formation of thyroid cancer cells. miR-145 is a potential target gene of TUG1, and miR-145/ZEB1 signal pathway mediates the function of TUG1 in thyroid cancer cells, implicating the potential application of TUG1 in the prognosis and treatment of thyroid cancer. This study provides more clues for the development of efficient therapeutic agents.
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